Brink's Q2 Keeps AMS/DRS on Track, Deal Timeline Accelerates — WAIT Thesis Holds

What happened

Brink's Q2 2026 results delivered 7% revenue growth, marking the 14th straight quarter of mid-teens or better AMS/DRS organic growth, with adjusted EBITDA up 11% and non-GAAP EPS jumping 18%. Management also flagged accelerating regulatory momentum that pulls the NCR Atleos acquisition closer, reducing the pendency timeline. The print confirms operational durability but does not signal a re-acceleration above the 2026 mid-to-high teens framework. While the faster deal close eases a key bear-case risk, the company's 4x net leverage and 24x P/E leave limited room for disappointment. Capital priorities remain locked on debt reduction, keeping shareholder returns subdued until post-close deleveraging materializes.

Implication

Investors should interpret the quarter as a de-risking event that solidifies the base case without elevating it to a bull thesis. A sooner close reduces uncertainties around regulatory drag and sales-cycle disruption, yet AMS/DRS growth holding at mid-teens rather than moving above 18% caps re-rating potential. Leverage at 4x net debt-to-EBITDA and interest coverage of 2.4x mean the equity remains vulnerable to any synergy or cost disappointment. The WAIT rating is reinforced—attractive entry still requires a pullback toward $105 or clearer post-close earnings power. Until deleveraging progresses and growth accelerates, the stock trades on execution confidence rather than undervaluation.

Thesis delta

Q2 execution and deal acceleration trim the bear-case probability but do not fulfill the bull trigger of 18%+ AMS/DRS growth. The investment thesis remains unchanged: solid operational performance supports base-case value around $125, yet high valuation and leverage argue for patience. Downside risk has narrowed, but upside is still restrained until leverage falls and growth re-accelerates.